TABLE 2.
Copy‐number alterations or nucleotide substitution mutations | The number of patients with each mutation | |||
---|---|---|---|---|
Metastasis | All (%, n = 60) | |||
Metastasis‐free (n = 34) | Late (≥1 y) (n = 8) | Early (<1 y) (n = 18) | ||
1p loss | 1 | 2 | 3 | 6 (10.0%) |
3p loss | 31 | 8 | 17 | 56 (93.3%) |
4p loss | 1 | 0 | 2 | 3 (5.0%) |
4q loss | 1 | 2 | 6 | 9 (15.0%) |
5p gain | 10 | 5 | 1 | 16 (26.7%) |
5q gain | 18 | 6 | 7 | 31 (51.7%) |
6q loss | 9 | 2 | 3 | 14 (23.3%) |
7 gain | 12 | 4 | 13 | 29 (48.3%) |
8p loss | 8 | 2 | 8 | 18 (30.0%) |
9p loss | 3 | 1 | 7 | 11 (18.3%) |
9q loss | 3 | 2 | 7 | 12 (20.0%) |
10q loss | 8 | 3 | 1 | 12 (20.0%) |
12 gain | 8 | 5 | 5 | 18 (30.0%) |
14q loss | 17 | 3 | 13 | 33 (55.0%) |
16p gain | 3 | 0 | 4 | 7 (11.7%) |
16q gain | 3 | 0 | 1 | 4 (6.7%) |
17p13 loss | 1 | 0 | 2 | 3 (5.0%) |
18 loss | 2 | 3 | 2 | 7 (11.7%) |
20 gain | 4 | 3 | 4 | 11 (18.3%) |
21q loss | 1 | 2 | 1 | 4 (6.7%) |
22 loss | 2 | 0 | 2 | 4 (6.7%) |
VHL | 28 | 8 | 14 | 50 (83.3%) |
PBRM1 | 14 | 6 | 8 | 28 (46.7%) |
SETD2 | 5 | 2 | 6 | 13 (21.7%) |
BAP1 | 4 | 1 | 7 | 12 (20.0%) |
The number of chromosome with CN alterations (median) | 3 | 5 | 6 | 4 |